Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early Relief
Bausch + Lomb Corporation (NYSE:BLCO) on Thursday reported topline Phase 2 results showing its topical eye drop BL1332 missed its primary pain-reduction endpoint after photorefractive keratectomy (PRK) surgery. PRK is a flapless laser eye surgery that reshapes the cornea to correct myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. The data showed it delivered consistent…
We haven't written up this one. Benzinga has the full story — the link below goes straight to it.